|
|
SPARTA, N.J. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,
|
|
|
|
--Bioequivalence study of VAZALORE 325 mg on track with top-line data demonstrating bioequivalence to immediate release aspirin-- --Shifting the date of sNDA filings for VAZALORE 325 mg and 81 mg doses earlier to mid-November 2020 -- --Targeting launch of VAZALORE 325 mg and 81 mg for third quarter
|
|
|
|
SPARTA, N.J. , Aug. 05, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,
|
|
|
|
SPARTA, N.J. , May 18, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer
|
|
|
|
-- Company to begin bioequivalence study of VAZALORE 325 mg dose -- -- sNDA submissions expected by year-end -- SPARTA, N.J. , May 15, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its
|
|
|
|
SPARTA, N.J. , May 04, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products,
|
|
|
|
-- Planning a Bioequivalence Study to Support VAZALORE 325 mg sNDA -- -- Announces $8 Million Convertible Preferred Stock Financing with Park West and MSD Partners -- SPARTA, New Jersey , March 13, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage
|
|
|
|
SPARTA, N.J. , March 03, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing more effective and safer products with its patent-protected PLxGuard™ delivery system, announced today that the Company will
|
|
|
|
VAZALORE’s novel mechanism of action ensures consistent aspirin bioavailability with administration in both fasting and fed conditions SPARTA, N.J. , Feb. 21, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on
|
|
|
|
SPARTA, N.J. , Jan. 07, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company initially focused on developing its clinically validated and patent-protected PLxGuard™ delivery system to provide more effective and safer
|
|
